Rakesh Popat, EHA, 2019 – Antigen Targets for Relapsed/Refractory Multiple Myeloma
We are joined by Rakesh Popat, from University College London Hospitals NHS Foundation Trust, at the EHA annual meeting in 2019 to discuss his presentation on the pursuit of antigen targets for relapsed/refractory multiple myeloma.
1. What are the current treatment options for relapsed/refractory multiple myeloma (MM) and what are their limitations? (0:05)
2. What is the rationale for targeting B-cell maturation antigen in relapsed/refractory MM? (1:20)
3. Could you tell us a little about the structure and mechanism of action of GSK2857916? (2:30)
4. Could you tell us about your phase I study investigating GSK2857916 and its findings? (3:22)
5. What were the findings of the study investigating patient-reported outcomes with GSK2857916? (4:40)
Dr Rakesh Popat has provided consultancy for GlaxoSmithKline Pharmaceuticals Ltd.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!